Similar to promyelocytic leukemia-retinoic acid receptor α (PML-RARA) rearrangement, NPM1 can also serve as a marker for the surveillance of minimal residual disease (MRD) in AML patients. This evidence concerns the gene NPM1 and acute promyelocytic leukemia.